Lineage Cell Therapeutics Q2 net loss $5.8M as revenue falls 56% to $1.4M

Lineage Cell Therapeutics, Inc.

2024-Q2 EPS reported -$0.07 revenue$2,852,000

Net loss attributable to Lineage $5.8M ($0.03/share) vs $5.2M prior year; revenue $1.4M vs $3.2M.
Cash and equivalents $38.5M as of June 30; expected to fund operations into Q4 2025.
OpRegen Phase 1/2a data: mean BCVA gain +5.5 letters at 24 months in less advanced GA patients (n=10).
OPC1 spinal cord injury study startup activities ongoing; hosted 2nd Annual SCI Investor Symposium.
Services agreement with Genentech initiated for OpRegen development support, fully funded by Genentech.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.